Quick Answer
NOVAVAX INC reported Research And Development Expense of $342.32 million for the year ending 2025.
- NOVAVAX INC showed a decrease of -12.5% in Research And Development Expense from 2024 to 2025.
- This data is from NOVAVAX INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: $6.33 million | Q3 2010: $7.87 million | Q1 2011: $5.07 million | Q2 2011: $4.35 million | Q3 2011: $4.05 million | Q1 2012: $5.34 million | Q2 2012: $5.37 million | Q3 2012: $6.64 million | Q1 2013: $9.26 million | Q2 2013: $10.79 million | Q3 2013: $13.95 million | Q1 2014: $14.52 million | Q2 2014: $15.20 million | Q3 2014: $19.22 million | Q1 2015: $28.35 million | Q2 2015: $27.73 million | Q3 2015: $30.66 million | Q1 2016: $68.95 million | Q2 2016: $64.90 million | Q3 2016: $52.98 million | Q1 2017: $37.65 million | Q2 2017: $39.26 million | Q3 2017: $41.86 million | Q1 2018: $44.51 million | Q2 2018: $44.54 million | Q3 2018: $41.33 million | Q1 2019: $35.47 million | Q2 2019: $30.42 million | Q3 2019: $18.61 million | Q1 2020: $16.90 million | Q2 2020: $34.85 million | Q3 2020: $294.09 million | Q1 2021: $592.67 million | Q2 2021: $570.69 million | Q3 2021: $408.20 million | Q1 2022: $383.48 million | Q2 2022: $289.65 million | Q3 2022: $304.30 million | Q1 2023: $247.10 million | Q2 2023: $219.48 million | Q3 2023: $106.23 million | Q1 2024: $92.68 million | Q2 2024: $106.95 million | Q3 2024: $87.16 million | Q1 2025: $88.94 million | Q2 2025: $79.23 million | Q3 2025: $98.27 million.
- Over the full 17 years of available data (2009 to 2025), NOVAVAX INC's Research And Development Expense has grown by 1,227.9%.
- Historical annual values: Fiscal year 2025: $342.32 million | Fiscal year 2024: $391.17 million | Fiscal year 2023: $737.50 million | Fiscal year 2022: $1.24 billion | Fiscal year 2021: $2.53 billion | Fiscal year 2020: $747.03 million | Fiscal year 2019: $113.84 million | Fiscal year 2018: $173.80 million | Fiscal year 2017: $168.44 million | Fiscal year 2016: $237.94 million | Fiscal year 2015: $162.64 million | Fiscal year 2014: $94.42 million | Fiscal year 2013: $58.53 million | Fiscal year 2012: $26.91 million | Fiscal year 2011: $18.36 million | Fiscal year 2010: $28.03 million | Fiscal year 2009: $25.78 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: